- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798325
Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient Mobility in Daily Living (DT4RD)
Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient
The low prevalence of rare diseases hinders the design of clinical studies with sufficient statistical power to demonstrate the efficacy of new drugs. This can only be achieved by setting up international multicentre studies, which is challenging due to a lack of objective, universal outcome measures that generate high-quality, reproducible data. One of the hurdles in attaining universal outcome measures for clinical trials is the difficulty to capture and distinguish ambulatory from non-ambulatory, autonomous and assistive or involuntary movements. This makes a trial assessing the ambulatory phase very challenging at this moment. Excluding many participants from trials and many patients from access to medication.
Integration and validation of the technology in trials, research and patients' lives is essential in overcoming this hurdle. For example, in dystrophinopathies separate outcome measures exist for ambulant and non-ambulant participants, but the relation between these outcome measures or a transitional outcome measure/end point is largely missing.
Following an exhaustive literature review, several tools have been selected to remotely follow various symptoms of neuromuscular patients including weakness, pain, fatigue, cognitive defects, motor impairments (including loss of dexterity, ataxia...), metabolic, respiratory and cardiac troubles, contractures, tremor, falls, hypo or hypersomnia... The toolbox includes common measures for all patients but may include additional measures specific to the patient's symptoms (hence in turn to the patients' disease).
The measurements are designed to not be invasive, intrusive or burdensome for the patient.
DT4RD is going to leverage state-of-the art technology, clinical rating scales and psychometric/data analysis to deliver fit for purpose remote clinical assessments of mobility to ensure maximum patient benefit, specifically:
- Compare face to face clinical data collected in hospital with Patient Generated Data recorded remotely
- Examine how sensors can enhance measurement potentially at home and during clinical visits
- Promote a clear focus on user centered design and the integration of technology
- Use reliability and validity analyses to equate any common measures (those with the same or a similar construct)
- Demonstrate a proof-of-concept model into which different measures can be interchangeable
Study Overview
Status
Conditions
Intervention / Treatment
- Other: 2MWT
- Other: MFM32
- Other: MyoGrip
- Other: QOL-gNMD
- Diagnostic test: Spirometry
- Device: Acceleromerty
- Other: 10mWT
- Other: PUL
- Other: NSAA
- Other: NSAD
- Other: TANS
- Other: MyoPinch
- Other: MyoQuad
- Other: ACTIVLIM
- Other: PREM
- Other: SF-MPQ
- Other: FSS
- Other: IPAQ
- Other: Rang of motion
- Device: Goniometry
- Other: Video captured monitoring
- Device: Activity monitoring
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Association Institut de Myologie
-
Principal Investigator:
- Giorgia QUERIN, MD
-
Contact:
- Vincent MD Varlet
- Phone Number: +33 1 42 16 58 58
- Email: v.varlet@institut-myologie.org
-
-
-
-
-
Newcastle Upon Tyne, United Kingdom, NE1 3BZ
- Not yet recruiting
- John Walton Muscular Dystrophy Research Centre
-
Contact:
- Volker STRAUB, MD
- Email: volker.straub@ncl.ac.uk
-
Principal Investigator:
- Robert Muni Lofra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged between 12 and 60 years
- Patients with a genetically confirmed/molecular-proven neuromuscular or neurometabolic disease*
- Patients experiencing walking difficulties in the home and at high risk of limiting participation and walking outside of the home.
- Written informed consent
- Able to comply with all protocol requirements, including video recording
- Affiliated to or beneficiary of a social security scheme (for France)
Exclusion Criteria:
- Patients with undefined diagnosis or any diagnosis other than neuromuscular or neurometabolic disease
- Patient walking 10m in less than 10s
- Guardianship/trusteeship
- Pregnant or nursing women
- Patients having relevant concomitant pathologies that, in the appreciation of the investigator could interfere with protocol compliance
- Patients not being affiliated with local social security (for France)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Principal
|
Two minutes walk tests.
Other Names:
Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
Other Names:
The MyoGrip is a dynamometer for measuring grip strength.
The "Quality of Life in genetic Neuromuscular Disease" questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage
Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g.
Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
Other Names:
The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub.
The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
Other Names:
10 meters walking Test.
The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
Other Names:
The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
Other Names:
The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
Other Names:
This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
Other Names:
The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
Other Names:
The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
Other Names:
The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living.
The patient responds on a Likert-type scale ranging from 1 to 7.
Other Names:
This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
Other Names:
The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
Other Names:
The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub.
The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
Other Names:
Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:
Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global home evaluations' attendance
Time Frame: Through study completion, an average of 1 year
|
Proportion of home assessments carried out compared to the number of home assessments planned
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance with filling out questionnaires at home
Time Frame: Through study completion, an average of 1 year
|
Analysis of the proportion of replies to the questionnaires at home
|
Through study completion, an average of 1 year
|
Compliance regarding using of the spirometer at home
Time Frame: Through study completion, an average of 1 year
|
Analysis of the proportion of valid spirometry data collected at home
|
Through study completion, an average of 1 year
|
Compliance regarding using of the LINKS sensors device at home
Time Frame: Through study completion, an average of 1 year
|
Analysis of the proportion of usable accelerometry data collected at home
|
Through study completion, an average of 1 year
|
Compliance regarding using of the activity sensor at home
Time Frame: Through study completion, an average of 1 year
|
Analysis of the proportion of usable data collected at home using the smartwatch
|
Through study completion, an average of 1 year
|
Compliance regarding achievement of video tasks at home
Time Frame: Through study completion, an average of 1 year
|
Analysis of the usability of the video tasks performed at home
|
Through study completion, an average of 1 year
|
Correlation of home and hospital spirometer Forced vital capacity measurements
Time Frame: Through study completion, an average of 1 year
|
Comparison of Forced vital capacity data collected during home and hospital spirometer measurements
|
Through study completion, an average of 1 year
|
Correlation of home and hospital spirometer peak expiratory flow measurements
Time Frame: Through study completion, an average of 1 year
|
Comparison of Peak expiratory flow data collected during home and hospital spirometer measurements
|
Through study completion, an average of 1 year
|
Correlation of home and hospital spirometer forced expiratory volume in 1 second measurements
Time Frame: Through study completion, an average of 1 year
|
Comparison of forced expiratory volume in 1 second data collected during home and hospital spirometer measurements
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DT4RD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Diseases
-
Brugmann University HospitalCompletedAnesthesia, General | Neuromuscular Transmission DisordersBelgium
-
University Hospital, ToursCompletedNeuromuscular Diseases in Children | Neuromuscular Diseases in InfantsFrance
-
Ottawa Hospital Research InstituteRecruiting
-
University of FloridaTerminated
-
Penwest Pharmaceuticals Co.TerminatedNeuromuscular DiseaseUnited Kingdom
-
National Institute of Nursing Research (NINR)TerminatedNeuromuscular DiseaseUnited States
-
Landon Pediatric FoundationCompleted
-
Institut de Myologie, FranceCompleted
-
Linde AGCompletedFunctional Test, COPD, Neuromuscular Disorders, Mechanical Ventilation, Weaning, DisabilityArgentina, Colombia, Germany
Clinical Trials on 2MWT
-
Istanbul University - Cerrahpasa (IUC)CompletedMultiple Sclerosis | Gait Disorders, Neurologic | Upper Extremity ProblemTurkey
-
University Hospital, AngersUnknownAmputation | Lower Extremity
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruiting